ppharmПедиатрическая фармакологияPediatric pharmacology1727-57762500-3089Издательство «ПедиатрЪ»10.15690/pf.v11i3.1020ppharm-109Research ArticleОБУЧЕНИЕ ОБУЧАЮЩИХ — ОБРАЗОВАТЕЛЬНЫЕ ПРОГРАММЫ ДЛЯ РОДИТЕЛЕЙTRAINING FOR TRAINERS — EDUCATIONAL PROGRAM FOR PARENTSКОМБИНИРОВАННАЯ ВАКЦИНА — ЭФФЕКТИВНАЯ И БЕЗОПАСНАЯ ЗАЩИТА ОТ ПЯТИ УПРАВЛЯЕМЫХ ИНФЕКЦИЙCOMBINED VACCINE IS AN EFFECTIVE AND SAFE PROTECTION FROM FIVE CONTROLLABLE INFECTIONSНовиковаД. А.NovikovaD. A.

кандидат медицинских наук, заведующая отделением вакцинопрофилактики детей с отклонениями в состоянии здоровья (раздел «Наука») ФГБУ «Научный центр здоровья детей»

MD, head of the vaccinal prevention department for children with health deviations (division “Science”) at the Scientific Center of Children’s Health (Federal State Budgetary Institution)

neonatepearl@yandex.ruТкаченкоН. Е.TkachenkoN. E.Научный центр здоровья детей, МоскваРоссияScientific Center of Children’s Health, MoscowRussian FederationНаучный центр здоровья детей, МоскваРоссияScientific Centre of Children’s Health, Moscow, Russian FederationRussian Federation201403062014113Педиатрическая фармакология107110Copyright © Новикова Д.А., Ткаченко Н.Е., 20142014Новикова Д.А., Ткаченко Н.Е.Novikova D.A., Tkachenko N.E.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://www.pedpharma.ru/jour/article/view/109

The article is dedicated to prevention of controllable infections in infants. This is an urgent issue, as up to 40 mln. infectious diseases are registered in Russia every year; infections are particularly prevalent in children. Infectious pathologies may take up to 70% of all health conditions in children. Vaccination is the only effective method of preventing infectious diseases. The authors present international experience of using a pentavalent vaccine, which contains diphtherial and tetanus toxoids, acellular pertussis component, inactivated poliovirus and type b Haemophilus influenzae polysaccharide. This vaccine is included into immune prevention schedules for children of 0-1 (primary vaccination) and 1-2 (revaccination) years of age in many countries. The article presents results of major clinical studies, which confirm low reactogenicity and high effectiveness of the mentioned vaccine.

 

инфекционные болезнипрофилактикавакцинацияпятивалентная комбинированная вакцинаэффективностьбезопасностьдетиinfectious diseasespreventionvaccinationpentavalent combined vaccineeffectivenesssafetychildrenReferencesURL: http://www.rospotrebnadzor.ruAvailable at: http://www.rospotrebnadzor.ruТаточенко В. К., Озерецковский Н. А., Фёдоров А. М. Иммунопрофилактика-2014. Москва: ПедиатрЪ. 2014. 198 с.Tatochenko V.K., Ozeretskovskii N.A., Fedorov A.M. Immunoprofilaktika-2014 [Immunoprophylaxis-2014]. Moscow, Pediatr"", 2014. 198 p.Учайкин В. Ф. Инфекционные болезни у детей. М.: ГЭОТАР-Медиа. 2011.Uchaikin V. F. Infektsionnye bolezni u detei [Infectious Diseases in Children]. Moscow, GEOTAR-Media, 2011.WHO. URL: http://www.who.int/immunization_monitoring/burden/Pneumo_hib_estimates/en/WHO. Available at: http://www.who.int/immunization_monitoring/burden/Pneumo_hib_estimates/en/WHO/UNICEF Ending Preventable Child Deaths From Pneumonia and Diarrhoea by 2025: The integrated Global Action Plan for Pneumonia and Diarrhoea (GAPPD). Geneva. 2013. URL: http://www.who.int/maternal_child_adolescent/news_events/news/2013/gappd_launch/en/WHO/UNICEF Ending Preventable Child Deaths From Pneumonia and Diarrhoea by 2025: The integrated Global Action Plan for Pneumonia and Diarrhoea (GAPPD). Geneva. 2013. Available at: http://www.who.int/maternal_child_adolescent/news_events/news/2013/gappd_launch/en/Plotkin S. A., Liese J., Madhi S. A. et al. A DTaP-IPV//PRP~T vaccine (Pentaxim): a review of 16 years' clinical experience. Expert Rev Vaccines. 2011 Jul; 10 (7): 981–1005.Plotkin S. A., Liese J., Madhi S. A. et al. A DTaP-IPV//PRP~T vaccine (Pentaxim): a review of 16 years' clinical experience. Expert Rev. Vaccines. 2011 Jul; 10 (7): 981–1005.Nelson J. C., Onchee Yu., Clara P. Dominguez-Islas Adapting Group Sequential Methods to Observational Postlicensure Vaccine Safety Surveillance: Results of a Pentavalent Combination DTaP-IPV-Hib Vaccine Safety Study. American Jornal of Epidemiology. 2013; 177 (Issue 2): 131–141.Nelson J. C., Onchee Yu., Clara P. Dominguez-Islas Adapting Group Sequential Methods to Observational Postlicensure Vaccine Safety Surveillance: Results of a Pentavalent Combination DTaP-IPVHib Vaccine Safety Study. American Jornal of Epidemiology. 2013;177 (Issue 2): 131–141.Capeding M. R., Cadorna-Carlos J. et al. Immunogencity and safety of DTaP-IPV. PRP-T combination vaccine given with hepatitis B vaccine: A randomized open lable trial. Bull. World Health Organ. 2008; 86 (6): 443–451.Capeding M. R., Cadorna-Carlos J. et al. Immunogencity and safety of DTaP-IPV. PRP-T combination vaccine given with hepatitis B vaccine: A randomized open lable trial. Bull. World Health Organ. 2008; 86 (6): 443–451.Madhi S. A., Cutland C. et al. Immunogenicity and safety of acellular pertussis, diphtheria, tetanus, inactivated poliovirus, Hib-conjugate combined vaccine (Pentaxim) and monovalent hepatitis B vaccine at 6, 10 and 14 month of age in infants of South Africa. S Afr Med J. 2011; 101: 126–131.Madhi S. A., Cutland C. et al. Immunogenicity and safety of acellular pertussis, diphtheria, tetanus, inactivated poliovirus, Hib-conjugate combined vaccine (Pentaxim) and monovalent hepatitis B vaccine at 6, 10 and 14 month of age in infants of South Africa. S Afr Med J. 2011; 101: 126–131.Gustavsson L., Hessel L. et al. Long-term follow-up of Swedish children vaccinated with acellular pertussis vaccines at 3, 5 andGustavsson L., Hessel L. et al. Long-term follow-up of Swedish children vaccinated with acellular pertussis vaccines at 3, 5 and 12 months of age indicates the need for a booster dose at 5 to 7 years of age. Pediatr. 2006; 118 (930): 978–984.months of age indicates the need for a booster dose at 5 to 7 years of age. Pediatr. 2006; 118 (930): 978–984.Thierry-Carstensen B., Dalby T. et al. Expirience of monocomponent acellular pertussis combination vaccines for infant, children, adolescents and adults. A review of safety, immunogenicity, efficacy and effectiveness studies and 15 years of field experience. Vaccine. 2013; 31: 5178–5191.Thierry-Carstensen B., Dalby T. et al. Expirience of mono-component acellular pertussis combination vaccines for infant, children, adolescents and adults. A review of safety, immunogenicity, efficacy and effectiveness studies and 15 years of field experience. Vaccine. 2013; 31: 5178–5191.Baranov A.A., Namazova-Baranova L.S., Galitskaya M.G. Immunoprofilaktika u detei. Chast' I. Vaktsinoprofilaktika u detei [Immunoprophylaxis in Children. Volume 1. Preventive Vaccination in Children]. Moscow, Pediatr"", 2012. 82 p.Баранов А.А., Намазова-Баранова Л.С., Галицкая М.Г. Иммунопрофилактика у детей. Часть I. Вакцинопрофилактика у детей. М.: ПедиатрЪ, 2012. 82 с.Баранов А.А., Намазова-Баранова Л.С., Галицкая М.Г. Иммунопрофилактика у детей. Часть I. Вакцинопрофилактика у детей. М.: ПедиатрЪ, 2012. 82 с.

The authors declare that there are no conflicts of interest present.